Publications

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.

Peer-Reviewed Original Research

Publications

2025

The STEP Learning Collaborative: A statewide Learning Healthcare System (LHS) for first episode psychosis

Deep multimodal representations and classification of first-episode psychosis via live face processing

The impact of Duration of Untreated Psychosis on functioning and quality of life over one year of Coordinated Specialty Care (CSC)

Sex differences in clozapine prescription: results from an Italian 30-year health records registry

Measurement properties of instruments to assess insight in psychosis: A systematic review protocol

Insight and suicidality in first-episode psychosis: The mediating role of depression

2024

The Academic Community Early Psychosis Intervention Network: Toward building a novel learning health system across six US states

The anomalous effect of COVID-19 pandemic restrictions on the duration of untreated psychosis

TimelinePTC: Development of a unified interface for pathways to care collection, visualization, and collaboration in first episode psychosis

The Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program

Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Correction: On the proportion of patients who experience a prodrome prior to psychosis onset: a systematic review and meta-analysis

On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis

The impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction

Role of Early Psychosis Detection in the Relationship Between Personal Income and Duration of Untreated Psychosis

Schizophrenia, A Practical Primer

2023

The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service

Towards a youth mental health paradigm: a perspective and roadmap

Aberrant Hierarchical Prediction Errors Are Associated With Transition to Psychosis: A Computational Single-Trial Analysis of the Mismatch Negativity

579. Benchmarking Observational Analyses Against Randomized Trial Results: An Application to First Episode Psychosis

Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis

2022

DUP redux: Observations vs. experiments in early intervention (invited commentary on Nkire et al.)

Granular analysis of pathways to care and durations of untreated psychosis: A marginal delay model

Promoting the Success and Sustainability of Coordinated Specialty Care Teams in Ohio